Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Operating Income : $-22.30 Mil (TTM As of Dec. 2020)

View and export this data going back to 2005. Start your Free Trial

What is Sunesis Pharmaceuticals Operating Income?

Sunesis Pharmaceuticals's Operating Income for the three months ended in Dec. 2020 was $-5.69 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2020 was $-22.30 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Sunesis Pharmaceuticals's Operating Income for the three months ended in Dec. 2020 was $-5.69 Mil. Sunesis Pharmaceuticals's Revenue for the three months ended in Dec. 2020 was $0.00 Mil. Therefore, Sunesis Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2020 was %.

Sunesis Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sunesis Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2020 was -1,015.94%. Sunesis Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2020 was -5,638.71%.

Sunesis Pharmaceuticals Operating Income Historical Data

The historical data trend for Sunesis Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Operating Income Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Operating Income

Get a 7-Day Free Trial

-36.46

-34.42

-25.71

-23.29

-22.30

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Operating Income	Get a 7-Day Free Trial															-5.35	-5.80	-6.35	-4.47	-5.69

Sunesis Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.30 Mil.

Sunesis Pharmaceuticals (NAS:SNSS) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sunesis Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2020 is calculated as:

	ROC % (Q: Dec. 2020 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2020 )	+	Invested Capital (Q: Dec. 2020 ))	/ count )
=	-22.752 * ( 1 - 0% )	/	( (1.719	+	2.76)	/ 2 )
=	-22.752	/	2.2395
=	-1,015.94 %

where

	Invested Capital		(Q: Sep. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	28.033	-	2.257	-	( 26.048	-	max(0, 3.567	-	27.624	+	26.048	))
=	1.719

	Invested Capital		(Q: Dec. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	23.247	-	1.653	-	( 20.41	-	max(0, 3.31	-	22.144	+	20.41	))
=	2.76

Note: The Operating Income data used here is four times the quarterly (Dec. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

Sunesis Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2020 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2020 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2020		Q: Dec. 2020
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-19.228	/	( ( (0.409 + max(-1.582, 0))	+	(0.273 + max(-1.303, 0)) )	/	2 )
=	-19.228	/	( ( 0.409	+	0.273 )	/	2 )
=	-19.228	/	0.341
=	-5,638.71 %

where Working Capital is:

	Working Capital		(Q: Sep. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.576)	-	(2.257	+	0	+	0.901)
=	-1.582

	Working Capital		(Q: Dec. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.734)	-	(1.653	+	0	+	1.384)
=	-1.303

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2020) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Sunesis Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2020 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2020 )	/	Revenue (Q: Dec. 2020 )
	=	-5.688	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Sunesis Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (NAS:SNSS) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Executives

Steve Carchedi	director	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Nicole Onetto	director	58 S SERVICE RD, MELVILLE NY 11747
Henry Ward Wolff	director	6701 KAISER DRIVE, FREMONT CA 94555
Steven B Ketchum	director	2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
James W Young	director
Homer L Pearce	director	84 CLIFDEN, ZIONSVILLE IN 46077
Dayton Misfeldt	director, officer: See Remarks	C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
David C Stump	director
Tina Gullotta	officer: VP, Finance	SUNESIS PHARMACEUTICALS,INC, 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William P. Quinn	officer: See Remarks	SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Judith A. Fox	officer: See Remarks	SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Aisling Capital Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms	10 percent owner	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Aisling Capital Partners Iv Llc	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106